Autobio Diagnostics Co Ltd (SHG:603658) — Market Cap & Net Worth
Market Cap & Net Worth: Autobio Diagnostics Co Ltd (603658)
Autobio Diagnostics Co Ltd (SHG:603658) has a market capitalization of $2.92 Billion (CN¥19.98 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #5048 globally and #878 in its home market, demonstrating a 10.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autobio Diagnostics Co Ltd's stock price CN¥34.97 by its total outstanding shares 571424768 (571.42 Million). Also see 603658 total assets for a full breakdown of the balance sheet.
Autobio Diagnostics Co Ltd Market Cap History: 2016 to 2026
Autobio Diagnostics Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $3.27 Billion to $2.92 Billion (0.76% CAGR). Also see Autobio Diagnostics Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Autobio Diagnostics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autobio Diagnostics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Autobio Diagnostics Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.70x
Autobio Diagnostics Co Ltd's market cap is 0.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.77x
Autobio Diagnostics Co Ltd's market cap is 2.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.27 Billion | $980.22 Million | $349.76 Million | 3.33x | 9.34x |
| 2017 | $3.20 Billion | $1.40 Billion | $446.56 Million | 2.28x | 7.16x |
| 2018 | $2.97 Billion | $1.93 Billion | $562.57 Million | 1.54x | 5.28x |
| 2019 | $5.92 Billion | $2.68 Billion | $774.16 Million | 2.21x | 7.65x |
| 2020 | $8.97 Billion | $2.98 Billion | $747.79 Million | 3.01x | 12.00x |
| 2021 | $4.47 Billion | $3.77 Billion | $973.66 Million | 1.19x | 4.59x |
| 2022 | $5.10 Billion | $4.44 Billion | $1.17 Billion | 1.15x | 4.36x |
| 2023 | $4.77 Billion | $4.44 Billion | $1.22 Billion | 1.07x | 3.92x |
| 2024 | $3.65 Billion | $4.47 Billion | $1.19 Billion | 0.82x | 3.06x |
| 2025 | $2.96 Billion | $4.23 Billion | $1.07 Billion | 0.70x | 2.77x |
Competitor Companies of 603658 by Market Capitalization
Companies near Autobio Diagnostics Co Ltd in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Autobio Diagnostics Co Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Autobio Diagnostics Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #122 globally with a market cap of $180.30 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #237 globally with a market cap of $105.52 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #122 | Abbott Laboratories | NYSE:ABT | $180.30 Billion | $103.69 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $90.77 |
| #237 | Stryker Corporation | NYSE:SYK | $105.52 Billion | $275.09 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Autobio Diagnostics Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Autobio Diagnostics Co Ltd's market cap moved from $3.27 Billion to $ 2.92 Billion, with a yearly change of 0.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.92 Billion | -1.27% |
| 2025 | CN¥2.96 Billion | -18.84% |
| 2024 | CN¥3.65 Billion | -23.45% |
| 2023 | CN¥4.77 Billion | -6.45% |
| 2022 | CN¥5.10 Billion | +14.10% |
| 2021 | CN¥4.47 Billion | -50.24% |
| 2020 | CN¥8.97 Billion | +51.48% |
| 2019 | CN¥5.92 Billion | +99.58% |
| 2018 | CN¥2.97 Billion | -7.17% |
| 2017 | CN¥3.20 Billion | -2.10% |
| 2016 | CN¥3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Autobio Diagnostics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.92 Billion USD |
| MoneyControl | $2.92 Billion USD |
| MarketWatch | $2.92 Billion USD |
| marketcap.company | $2.92 Billion USD |
| Reuters | $2.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more